ECSP088949A - Polipéptidos de factor de crecimiento de tipo insulina estabilizada - Google Patents

Polipéptidos de factor de crecimiento de tipo insulina estabilizada

Info

Publication number
ECSP088949A
ECSP088949A EC2008008949A ECSP088949A ECSP088949A EC SP088949 A ECSP088949 A EC SP088949A EC 2008008949 A EC2008008949 A EC 2008008949A EC SP088949 A ECSP088949 A EC SP088949A EC SP088949 A ECSP088949 A EC SP088949A
Authority
EC
Ecuador
Prior art keywords
growth factor
type growth
factor polypeptides
insulin type
stabilized insulin
Prior art date
Application number
EC2008008949A
Other languages
English (en)
Inventor
David Jonathan Glass
Mara Fornaro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088949A publication Critical patent/ECSP088949A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

La invención se refiere a polipéptidos estabilizados que tienen una secuencia de IGF-1 o IGF-2 y una secuencia de péptido E, en donde la escisión fisiológica natural del péptido E a partir de IGF es evitada.
EC2008008949A 2006-06-09 2008-12-09 Polipéptidos de factor de crecimiento de tipo insulina estabilizada ECSP088949A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81234906P 2006-06-09 2006-06-09
US86224406P 2006-10-20 2006-10-20
US89718707P 2007-01-24 2007-01-24

Publications (1)

Publication Number Publication Date
ECSP088949A true ECSP088949A (es) 2009-01-30

Family

ID=38801859

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008949A ECSP088949A (es) 2006-06-09 2008-12-09 Polipéptidos de factor de crecimiento de tipo insulina estabilizada

Country Status (33)

Country Link
US (4) US8343918B2 (es)
EP (2) EP2032155B1 (es)
JP (2) JP2009539805A (es)
KR (1) KR101459789B1 (es)
AR (1) AR061242A1 (es)
AU (2) AU2007257936B2 (es)
BR (2) BRPI0712147A2 (es)
CA (2) CA2653781A1 (es)
CL (1) CL2007001614A1 (es)
CR (2) CR10432A (es)
CY (1) CY1116117T1 (es)
DK (2) DK2032155T3 (es)
EC (1) ECSP088949A (es)
ES (1) ES2529261T3 (es)
GT (1) GT200800273A (es)
HK (1) HK1126429A1 (es)
HR (1) HRP20150326T1 (es)
IL (1) IL195156A (es)
JO (1) JO2968B1 (es)
MA (1) MA30503B1 (es)
MX (2) MX2008015657A (es)
MY (1) MY147856A (es)
NO (2) NO20085183L (es)
NZ (2) NZ572708A (es)
PE (1) PE20080715A1 (es)
PL (1) PL2032155T3 (es)
PT (1) PT2032155E (es)
RU (1) RU2477287C2 (es)
SI (1) SI2032155T1 (es)
TN (1) TNSN08509A1 (es)
TW (1) TWI427084B (es)
UA (1) UA97953C2 (es)
WO (2) WO2007141309A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318355A1 (en) * 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
MY147856A (en) 2006-06-09 2013-01-31 Novartis Ag Stabilized insulin-like growth factor polypeptides
AU2009244148B2 (en) * 2008-05-07 2014-10-09 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
CA2743072A1 (en) * 2008-11-10 2010-05-14 Novartis Ag Antibodies to modified human igf-1/e peptides
WO2010088502A2 (en) * 2009-01-30 2010-08-05 The Regents Of The University Of California Insulin-like growth factor signaling and integrin
WO2010125003A1 (en) 2009-04-27 2010-11-04 Novartis Ag Compositions and methods for increasing muscle growth
US8759299B2 (en) * 2009-07-22 2014-06-24 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59
EP2498796B1 (en) * 2009-11-09 2017-12-27 AAL Scientifics, Inc. Treatment of heart disease
JP2011160696A (ja) * 2010-02-08 2011-08-25 Novartis Ag 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
CN103458915A (zh) 2011-02-23 2013-12-18 麻省理工学院 水溶性膜蛋白及其制备和使用方法
US20140357558A1 (en) * 2011-06-24 2014-12-04 Cold Spring Harbor Laboratory Compositions and methods for treatment of spinal muscular atrophy
PT2726099T (pt) 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
WO2014012025A2 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Igf-1 proteins and therapeutic uses thereof
CN104884467A (zh) * 2012-12-18 2015-09-02 诺华股份有限公司 在遗传修饰的哺乳动物细胞中生产治疗性蛋白质
DK2935320T3 (da) 2012-12-18 2019-11-18 Novartis Ag Stabiliserede insulinlignende vækstfaktorpolypeptider
WO2015022658A2 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
CA2926173A1 (en) * 2013-10-02 2015-04-09 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) * 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
CA2933610C (en) 2013-12-19 2023-01-24 Puretein Bioscience Llc Methods for treating a viral infection using igf in an animal
US20170248609A1 (en) 2014-01-27 2017-08-31 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
BR112017016381A2 (pt) * 2015-02-04 2018-03-27 Puretein Bioscience Llc métodos para aumentar características de desempenho em proles
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
CA3054837A1 (en) 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease
JP6691503B2 (ja) * 2017-04-13 2020-04-28 任天堂株式会社 ゲームプログラム、ゲーム処理制御方法、およびゲーム装置
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2023145961A1 (ja) * 2022-01-31 2023-08-03 国立大学法人信州大学 ＩＧＦ１Ｒを標的とするｐｒｅ－ｐｒｏ前駆体型キメラ抗原受容体発現細胞

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU598205B2 (en) 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
EP0346429B1 (en) 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
JPH07508025A (ja) * 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
AU1178395A (en) 1993-11-12 1995-05-29 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
CA2190752A1 (en) 1994-05-24 1995-11-30 George N. Cox Modified insulin-like growth factors
GB9605124D0 (en) 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US7118752B2 (en) * 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
JP3971108B2 (ja) * 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
GB9926968D0 (en) 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
IL158418A0 (en) * 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
HUE027645T2 (en) * 2005-01-07 2016-10-28 Regeneron Pharma IGF-1 fusion proteins and therapeutic applications
AU2006224334A1 (en) 2005-03-18 2006-09-21 The Board Of Trustees Of The University Of Illinois Mecano growth factor peptides and their use
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
JP4713579B2 (ja) 2005-03-31 2011-06-29 パイオニア株式会社 アプリケーションプログラム
MY147856A (en) * 2006-06-09 2013-01-31 Novartis Ag Stabilized insulin-like growth factor polypeptides

Also Published As

Publication number Publication date
CR20160115A (es) 2016-06-14
GT200800273A (es) 2009-09-16
CA2653781A1 (en) 2007-12-13
JP2009539805A (ja) 2009-11-19
PE20080715A1 (es) 2008-07-25
NZ572548A (en) 2011-06-30
AU2007257936B2 (en) 2011-05-26
EP2032155A2 (en) 2009-03-11
ES2529261T3 (es) 2015-02-18
AU2007255419A1 (en) 2007-12-13
RU2008151511A (ru) 2010-07-20
IL195156A0 (en) 2011-08-01
PT2032155E (pt) 2015-04-07
NO20085184L (no) 2009-03-03
SI2032155T1 (sl) 2015-04-30
NZ572708A (en) 2011-11-25
TNSN08509A1 (en) 2010-04-14
WO2007146689A3 (en) 2008-04-10
IL195156A (en) 2014-07-31
TW200835698A (en) 2008-09-01
WO2007146689A2 (en) 2007-12-21
BRPI0712147A2 (pt) 2012-02-22
MX2008015657A (es) 2009-02-04
US20170066808A9 (en) 2017-03-09
UA97953C2 (uk) 2012-04-10
KR20090027197A (ko) 2009-03-16
JO2968B1 (en) 2016-03-15
AU2007257936A1 (en) 2007-12-21
BRPI0712052A2 (pt) 2012-01-10
AR061242A1 (es) 2008-08-13
WO2007141309A3 (en) 2008-05-29
HK1126429A1 (en) 2009-09-04
WO2007146689A9 (en) 2010-12-16
CL2007001614A1 (es) 2008-08-08
DK200900016A (da) 2009-01-06
CA2654944A1 (en) 2007-12-21
DK2032155T3 (en) 2015-03-02
CR10432A (es) 2009-01-15
JP5290966B2 (ja) 2013-09-18
US20100234290A1 (en) 2010-09-16
JP2009539383A (ja) 2009-11-19
US20100173839A1 (en) 2010-07-08
PL2032155T3 (pl) 2015-05-29
EP2032155B1 (en) 2014-12-24
CY1116117T1 (el) 2017-02-08
US8722621B2 (en) 2014-05-13
TWI427084B (zh) 2014-02-21
US8343918B2 (en) 2013-01-01
MA30503B1 (fr) 2009-06-01
HRP20150326T1 (hr) 2015-04-24
US20140235538A1 (en) 2014-08-21
MX2008015726A (es) 2008-12-19
RU2477287C2 (ru) 2013-03-10
EP2032154A2 (en) 2009-03-11
NO20085183L (no) 2009-03-09
MY147856A (en) 2013-01-31
CA2654944C (en) 2017-01-03
KR101459789B1 (ko) 2014-11-07
US20130059779A1 (en) 2013-03-07
WO2007141309A2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
ECSP088949A (es) Polipéptidos de factor de crecimiento de tipo insulina estabilizada
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
ES2575906T3 (es) Composiciones y métodos de producir metionina
PA8811501A1 (es) Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
ES2668967T3 (es) Inmunógenos de Escherichia coli con solubilidad mejorada
CR20120026A (es) Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv
WO2007104738A3 (en) Acylated single chain insulin
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
WO2007104736A3 (en) Acylated single chain insulin
BR112014012460A2 (pt) proteínas recombinantes e seus usos terapêuticos
MX2009012922A (es) Vacunacion intradermica de un peptido del virus del papiloma humano.
PE20121722A1 (es) Polipeptido de fusion contra tumor inducido por virus eb y mutante de colicina ia
ECSP099828A (es) Uso de ranolazina para peptido natriuretico tipo-cerebral elevado
WO2012058585A3 (en) Treatment of heart failure with natriuretic peptides
AR050887A1 (es) Modificacion del contenido de lignina en plantas
AR068340A1 (es) MEJORA DE LAS TOXICIDADES DE LAS PROTEINAS CRY DE BACILUS THURINGINESIS PARA LOS COLEoPTEROS Y FRAGMENTOS DE CADERINA DE INSECTOS
JP2009502208A5 (es)
MX2010010177A (es) Fragmentos de beta timosina mejorada.
NZ595060A (en) Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
DE602007010969D1 (de) Zytokinderivate